Bristol-Myers Squibb (NYSE:BMY – Get Rating) is set to issue its quarterly earnings data before the market opens on Friday, April 29th. Analysts expect the company to announce earnings of $1.93 per share for the quarter. Bristol-Myers Squibb has set its FY22 guidance at $7.65-7.95 EPS.Investors interested in listening to the company’s conference call can do so using this link.
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its quarterly earnings results on Friday, February 4th. The biopharmaceutical company reported $1.83 EPS for the quarter, hitting analysts’ consensus estimates of $1.83. Bristol-Myers Squibb had a return on equity of 45.60% and a net margin of 15.08%. The business had revenue of $11.96 billion during the quarter, compared to analysts’ expectations of $12 billion. During the same quarter last year, the company posted $1.46 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 8.0% on a year-over-year basis. On average, analysts expect Bristol-Myers Squibb to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.
NYSE BMY opened at $77.56 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.43 and a debt-to-equity ratio of 1.10. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $78.17. The company has a 50 day moving average of $71.62 and a 200-day moving average of $64.35. The company has a market cap of $169.06 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 1.47 and a beta of 0.55.
Several brokerages have commented on BMY. BMO Capital Markets boosted their price objective on shares of Bristol-Myers Squibb from $74.00 to $81.00 and gave the company an “outperform” rating in a research report on Wednesday, March 30th. StockNews.com began coverage on shares of Bristol-Myers Squibb in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Morgan Stanley decreased their target price on shares of Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 6th. Finally, Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $67.75.
In related news, CEO Giovanni Caforio sold 25,000 shares of the company’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $71.52, for a total value of $1,788,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christopher S. Boerner sold 29,532 shares of the stock in a transaction dated Monday, March 14th. The shares were sold at an average price of $69.20, for a total transaction of $2,043,614.40. The disclosure for this sale can be found here. In the last three months, insiders sold 165,668 shares of company stock worth $11,459,888. Insiders own 0.09% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Crestwood Advisors Group LLC grew its holdings in Bristol-Myers Squibb by 8.7% in the fourth quarter. Crestwood Advisors Group LLC now owns 5,517 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 441 shares during the last quarter. EverSource Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $45,000. KB Financial Partners LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $47,000. First Community Trust NA acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $64,000. Finally, Carroll Investors Inc acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $71,000. 72.00% of the stock is currently owned by institutional investors.
About Bristol-Myers Squibb (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
- Steel Dynamics Scales New Heights On Record Results
- The Institutions Are Driving Knight-Swift Transportation
- Tesla (NASDAQ: TSLA) Stock Hits Four Figures Once Again
- 3 Legendary Low-Beta Stocks Set to Outperform
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.